JPMorgan Chase & Co. Has $333,000 Stake in Perspective Therapeutics, Inc. (NYSE:CATX)

JPMorgan Chase & Co. increased its stake in Perspective Therapeutics, Inc. (NYSE:CATX) by 24.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 24,912 shares of the company’s stock after purchasing an additional 4,844 shares during the quarter. JPMorgan Chase & Co.’s holdings in Perspective Therapeutics were worth $333,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company boosted its stake in Perspective Therapeutics by 8.9% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after purchasing an additional 1,672 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Perspective Therapeutics by 5.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock valued at $783,000 after acquiring an additional 3,211 shares during the period. US Bancorp DE grew its stake in shares of Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after acquiring an additional 3,866 shares during the last quarter. nVerses Capital LLC bought a new position in Perspective Therapeutics during the third quarter worth $57,000. Finally, Intech Investment Management LLC acquired a new position in Perspective Therapeutics during the 3rd quarter valued at $137,000. Institutional investors own 54.66% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. UBS Group assumed coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 price objective on the stock. Oppenheimer cut their price target on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Wedbush restated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research note on Friday, January 24th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $16.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, Perspective Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $15.14.

Insider Transactions at Perspective Therapeutics

In other news, CEO Johan M. Spoor acquired 14,500 shares of Perspective Therapeutics stock in a transaction on Monday, November 25th. The shares were purchased at an average price of $3.78 per share, with a total value of $54,810.00. Following the acquisition, the chief executive officer now owns 152,072 shares in the company, valued at $574,832.16. This represents a 10.54 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Jonathan Robert Hunt bought 12,829 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were purchased at an average price of $3.82 per share, with a total value of $49,006.78. Following the transaction, the chief financial officer now owns 48,800 shares of the company’s stock, valued at $186,416. The trade was a 35.66 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 67,570 shares of company stock worth $256,789. Insiders own 3.52% of the company’s stock.

Perspective Therapeutics Trading Up 5.5 %

Perspective Therapeutics stock opened at $3.81 on Friday. The stock has a fifty day moving average price of $3.51 and a two-hundred day moving average price of $9.57. Perspective Therapeutics, Inc. has a 52-week low of $2.70 and a 52-week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). The firm had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. On average, equities research analysts predict that Perspective Therapeutics, Inc. will post -0.88 EPS for the current year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.